Our project aiming at overcoming chemotherapy resistance in TNBC via targeting lysyl oxidase (LOX) was chosen for presentation at National NIGMS IDeA Program Virtual Meeting – September 22, 2020. Our discovery of this novel drug resistance mechanism was recently published in one of the most selective and prestigious scientific journals (Nature Communications). We are hopeful that our findings will pave the way to develop novel drugs targeting LOX for the treatment of TNBC that do not respond to conventional therapies.

More information about the IDeA program and virtual meeting.

Categories: News


Leave a Reply

Avatar placeholder

Your email address will not be published. Required fields are marked *